Thematic review series : The Pathogenesis of Atherosclerosis An interpretive history of the cholesterol controversy , part V : The discovery of the statins and the end of the controversy 1
暂无分享,去创建一个
[1] D. Steinberg. Thematic review series: The Pathogenesis of Atherosclerosis. An interpretive history of the cholesterol controversy, part IV: The 1984 Coronary Primary Prevention Trial ends it—almost1 , 2006, Journal of Lipid Research.
[2] R. Collins,et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.
[3] A. Gotto. Over‐the‐counter statins and cardiovascular disease prevention: Perspectives, challenges, and opportunities , 2005, Clinical pharmacology and therapeutics.
[4] R. Bentley. The Development of Penicillin: Genesis of a Famous Antibiotic , 2005, Perspectives in biology and medicine.
[5] D. Steinberg. Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy: part II: the early evidence linking hypercholesterolemia to coronary disease in humans. , 2005, Journal of lipid research.
[6] François Mach,et al. Inflammation and Atherosclerosis , 2004, Herz.
[7] Michael S. Brown,et al. A tribute to Akira Endo, discoverer of a “Penicillin” for cholesterol , 2004 .
[8] D. Steinberg. Thematic review series: The Pathogenesis of Atherosclerosis. An interpretive history of the cholesterol controversy: part I Published, JLR Papers in Press, April 21, 2004. DOI 10.1194/jlr.R400003-JLR200 11 Based in part on The Cholesterol Wars, a book in preparation. , 2004, Journal of Lipid Research.
[9] H. Büller,et al. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study , 2004, JAMA.
[10] Neil J Stone,et al. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.
[11] J. Mckenney,et al. Treatment of High-Risk patients with ezetimibe plus simvastatin Co-Administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III Low-Density lipoprotein cholesterol goals , 2004 .
[12] Richard M. Moe,et al. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. , 2004, Journal of the American College of Cardiology.
[13] Paul Schoenhagen,et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. , 2004, JAMA.
[14] H. Brewer,et al. High-density lipoproteins: a new potential therapeutic target for the prevention of cardiovascular disease. , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[15] M. Davidson. Efficacy of Simvastatin and Ezetimibe in Treating Hypercholesterolemia In a recent editorial published in JACC , 2022 .
[16] R. Collins,et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial , 2003, The Lancet.
[17] Christopher K. Glass,et al. Atherosclerosis The Road Ahead , 2001, Cell.
[18] S. Goodman. Toward Evidence-Based Medical Statistics. 1: The P Value Fallacy , 1999, Annals of Internal Medicine.
[19] Steven Goodman. Toward Evidence-Based Medical Statistics. 2: The Bayes Factor , 1999, Annals of Internal Medicine.
[20] A. Gotto,et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.
[21] Terje R Pedersen,et al. Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) , 1997, Diabetes Care.
[22] P. Macfarlane,et al. West of Scotland Coronary Prevention Study: Identification of high-risk groups and comparison with other cardiovascular intervention trials , 1996 .
[23] J. Tobert. Statin therapy and CHD , 1996, The Lancet.
[24] P. Macfarlane,et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .
[25] J. Slattery,et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.
[26] G. Hansson,et al. Immune mechanisms in atherosclerosis. , 1994, Coronary artery disease.
[27] J. Huttunen,et al. The Helsinki Heart Study: an 8.5‐year safety and mortality follow‐up , 1994, Journal of internal medicine.
[28] J. Mckenney,et al. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) , 1993, JAMA.
[29] A. Endo,et al. The discovery and development of HMG-CoA reductase inhibitors. , 1992, Journal of lipid research.
[30] S. Yusuf,et al. Report of the Conference on Low Blood Cholesterol: Mortality Associations , 1992, Circulation.
[31] R Peto,et al. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. , 1991, BMJ.
[32] D. Steinberg,et al. The cholesterol controversy is over. Why did it take so long? , 1989, Circulation.
[33] A. Endo. Chemistry, biochemistry, and pharmacology of HMG-CoA reductase inhibitors , 1988, Klinische Wochenschrift.
[34] M. Brown,et al. A receptor-mediated pathway for cholesterol homeostasis. , 1986, Science.
[35] M. Brown,et al. Appearance of crystalloid endoplasmic reticulum in compactin-resistant Chinese hamster cells with a 500-fold increase in 3-hydroxy-3-methylglutaryl-coenzyme A reductase. , 1982, Proceedings of the National Academy of Sciences of the United States of America.
[36] H. Mabuchi,et al. Effects of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase on serum lipoproteins and ubiquinone-10 levels in patients with familial hypercholesterolemia. 1981. , 1981, Atherosclerosis. Supplements.
[37] R Monaghan,et al. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. , 1980, Proceedings of the National Academy of Sciences of the United States of America.
[38] R. Fears,et al. The effect of compactin, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme-A reductase activity, on cholesterogenesis and serum cholesterol levels in rats and chicks. , 1980, Atherosclerosis.
[39] A. Endo,et al. Therapeutic effects of ML-236B in primary hypercholesterolemia. , 1980, Atherosclerosis.
[40] Endo Akira,et al. Effects of ML-236B on cholesterol metabolism in mice and rats: Lack of hypocholesterolemic activity in normal animals , 1979 .
[41] Y. Tsujita,et al. Hypolipidemic effects in monkeys of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase , 1979, Lipids.
[42] Y. Tsujita,et al. Hypolipidemic effects in dogs of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. , 1979, Atherosclerosis.
[43] M. Oliver. Cholesterol, coronaries, clofibrate and death. , 1978, The New England journal of medicine.
[44] M. Brown,et al. Induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts incubated with compactin (ML-236B), a competitive inhibitor of the reductase. , 1978, The Journal of biological chemistry.
[45] M. Pike,et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.
[46] M. Kuroda,et al. Competitive inhibition of 3‐hydroxy‐3‐methylglutaryl coenzyme a reductase by ML‐236A and ML‐236B fungal metabolites, having hypocholesterolemic activity , 1976, Atherosclerosis. Supplements.
[47] Y. Tsujita,et al. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. , 1976, The Journal of antibiotics.
[48] P. Armitage,et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. , 1976, British Journal of Cancer.
[49] J. Fine. Letter: Bacteraemic shock. , 1974, Lancet.
[50] G. Mills,et al. The distribution and composition of serum lipoproteins in eighteen animals. , 1971, Comparative biochemistry and physiology. B, Comparative biochemistry.
[51] J Cornfield,et al. The Bayesian outlook and its application. , 1969, Biometrics.
[52] J. Avigan,et al. Deposition of desmosterol in the lesions of experimental atherosclerosis. , 1962, Lancet.
[53] J. Avigan,et al. Identification of 24-dehydrocholesterol in the serum of patients treated with MER-29. , 1960, Progress in cardiovascular diseases.
[54] R. D. Mackenzie,et al. Specific inhibition of cholesterol biosynthesis by a synthetic compound (MER-29). , 1959, Archives of biochemistry and biophysics.
[55] J. Avigan,et al. Effects of δ4-Cholestenone in Animals and in Man , 1958, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[56] R. E. Peterson,et al. Inhibition of Adrenocortical Steroid Secretion by Δ4-Cholestenone , 1958 .
[57] G. S. Boyd,et al. Effect of phenylethylacetic acid and its amide (hyposterol) on the circulating lipids and lipoproteins in man. , 1957, Lancet.
[58] G. Tomkins,et al. Use of Δ4-Cholestenone to Reduce the Level of Serum Cholesterol in Man , 1957, Science.
[59] D. Steinberg,et al. Failure of Alpha‐Phenylbutyrate and Beta‐Phenylvalerate in Treatment of Hypercholesterolemia , 1957, Circulation.
[60] A KEYS,et al. Phenyl butyramide and the serum cholesterol concentration in man. , 1957, Metabolism: clinical and experimental.
[61] D. Steinberg,et al. INHIBITORS OF CHOLESTEROL BIOSYNTHESIS AND THE PROBLEM OF HYPERCHOLESTEROLEMIA , 1956, Annals of the New York Academy of Sciences.
[62] D. Steinberg,et al. Inhibition of Lipid Synthesis by Alpha-Phenyl-N-Butyrate and Related Compounds , 1955, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[63] J. Cottet,et al. [Therapeutic study of a synthetic hypocholesterolemic agent: phenyl-ethyl-acetic acid]. , 1954, La Presse medicale.
[64] G. Tomkins,et al. Cholesterol synthesis by liver. IV. Suppression by steroid administration. , 1953, The Journal of biological chemistry.
[65] J. Cottet,et al. [Hypocholesterolemic property of sodium phenylethylacetate (22 TH) in the rat]. , 1953, Bulletin de l'Academie nationale de medecine.
[66] A. Daemmrich. Medicine, Science, and Merck , 2004 .
[67] S. Grundy,et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[68] I.,et al. CHOLESTEROL SYNTHESIS BY LIVER , 2003 .
[69] S. Yusuf. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .
[70] Ames,et al. PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA , 2000 .
[71] HOMAS,et al. The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels , 2000 .
[72] W. Roberts,et al. Safety of fenofibrate--US and worldwide experience. , 1989, Cardiology.
[73] H. Mabuchi,et al. Effect of an inhibitor of 3-hydroxy-3-methyglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia. , 1981, The New England journal of medicine.
[74] Y. Tsujita,et al. Effects of ML-236B on cholesterol metabolism in mice and rats: lack of hypocholesterolemic activity in normal animals. , 1979, Biochimica et biophysica acta.
[75] A. Brown,et al. Crystal and molecular structure of compactin, a new antifungal metabolite from Penicillium brevicompactum. , 1976, Journal of the Chemical Society. Perkin transactions 1.
[76] D. Steinberg. Chemotherapeutic Approaches to the Problem of Hyperlipidemia , 1962 .
[77] J. Avigan,et al. Mechanism of action of MER-29, an inhibitor of cholesterol biosynthesis. , 1960, Biochemical and biophysical research communications.
[78] R. E. Peterson,et al. Inhibition of adrenocortical steroid secretion by delta 4-cholestenone. , 1958, Science.
[79] G. Tomkins,et al. [Use of delta 4-cholestenone to reduce the level of serum cholesterol in man]. , 1957, Science.